SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL)

This is a single-arm, multicenter, Phase Ib/IIa study designed to explore the efficacy and safety of SHR2554 in combination with liposomal mitoxantrone for the treatment of patients with treatment-naive peripheral T-cell lymphoma (PTCL). The study is divided into a Phase Ib safety lead-in phase and a Phase IIa dose expansion phase.

NCT Number	NCT07725705
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	PTCL, First Line Treatment
Enrollment	44 participants
Start Date	2026-08-01
Primary Completion	2028-08-01 (estimated)
Study Completion	2030-03-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-24